Ginkgo Bioworks Holdings Sees New Partnership and Potential Undervaluation
ByAinvest
Wednesday, Nov 19, 2025 12:42 am ET1min read
DNA--
Ginkgo Bioworks Holdings has partnered with the University of Illinois to advance oral health therapies through the ARPA-H funded MIGHTY initiative. Despite a 41% share price drop in the last month, the stock's 21% total shareholder return over the past year suggests investors still see growth potential in its biotech pipeline. The company is undervalued according to most popular narrative, with a fair value of $12, driven by ambitious profitability targets and future margins rarely seen in this sector. Strong traction in academic markets or successful monetization of new AI-powered data tools could change expectations for Ginkgo's long-term growth trajectory.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet